Search

Your search keyword '"Debilly, Bérangère"' showing total 13 results
Start Over Author "Debilly, Bérangère"
13 results on '"Debilly, Bérangère"'

6. Body weight gain and deep brain stimulation

Author

Rieu, Isabelle, Derost, Philippe, Ulla, Miguel, Marques, Ana, Debilly, Bérangère, De Chazeron, Ingrid, Chéreau, Isabelle, Lemaire, Jean Jacques, Boirie, Yves, Llorca, Pierre Michel, and Durif, Franck

Published
2011
Full Text
View/download PDF

7. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Corvol, Jean-Christophe, Elbaz, Alexis, Vidailhet, Marie, Brice, Alexis, Artaud, Fanny, Bourdain, Frédéric, Brandel, Jean-Philippe, Derkinderen, Pascal, Durif, Franck, Levy, Richard, Pico, Fernando, Rascol, Olivier, Bonnet, Anne-Marie, Bonnet, Cecilia, Brefel-Courbon, Christine, Cormier-Dequaire, Florence, Degos, Bertrand, Debilly, Bérangère, Galitsky, Monique, Grabli, David, Hartmann, Andreas, Klebe, Stephan, Kraemmer, Julia, Lacomblez, Lucette, Leder, Sara, Mangone, Graziella, Mariani, Louise-Laure, Marques, Ana-Raquel, Mesnage, Valérie, Muellner, Julia, Ory-Magne, Fabienne, Planté-Bordeneuve, Violaine, Roze, Emmanuel, Tir, Melissa, You, Hana, Benchetrit, Eve, Socha, Julie, Pineau, Fanny, Vidal, Tiphaine, Pomies, Elsa, Bayet, Virginie, Lesage, Suzanne, Tahiri, Khadija, Bertrand, Hélène, Mallet, Alain, Villeret, Coralie, Mazmanian, Merry, Manseur, Hakima, Hajji, Mostafa, Le Toullec, Benjamin, Brochard, Vanessa, Roy, Monica, Rieu, Isabelle, Bernard, Stéphane, Faurie-Grepon, Antoine, Ihle, J., Artaud, F., Bekadar, S., Mangone, G., Sambin, S., Mariani, LL, Bertrand, H., Rascol, O., Durif, F., Derkinderen, P., Scherzer, C., Elbaz, A., and Corvol, JC

Published
2020
Full Text
View/download PDF

8. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Ihle, J., primary, Artaud, F., additional, Bekadar, S., additional, Mangone, G., additional, Sambin, S., additional, Mariani, LL, additional, Bertrand, H., additional, Rascol, O., additional, Durif, F., additional, Derkinderen, P., additional, Scherzer, C., additional, Elbaz, A., additional, Corvol, JC, additional, Corvol, Jean-Christophe, additional, Elbaz, Alexis, additional, Vidailhet, Marie, additional, Brice, Alexis, additional, Artaud, Fanny, additional, Bourdain, Frédéric, additional, Brandel, Jean-Philippe, additional, Derkinderen, Pascal, additional, Durif, Franck, additional, Levy, Richard, additional, Pico, Fernando, additional, Rascol, Olivier, additional, Bonnet, Anne-Marie, additional, Bonnet, Cecilia, additional, Brefel-Courbon, Christine, additional, Cormier-Dequaire, Florence, additional, Degos, Bertrand, additional, Debilly, Bérangère, additional, Galitsky, Monique, additional, Grabli, David, additional, Hartmann, Andreas, additional, Klebe, Stephan, additional, Kraemmer, Julia, additional, Lacomblez, Lucette, additional, Leder, Sara, additional, Mangone, Graziella, additional, Mariani, Louise-Laure, additional, Marques, Ana-Raquel, additional, Mesnage, Valérie, additional, Muellner, Julia, additional, Ory-Magne, Fabienne, additional, Planté-Bordeneuve, Violaine, additional, Roze, Emmanuel, additional, Tir, Melissa, additional, You, Hana, additional, Benchetrit, Eve, additional, Socha, Julie, additional, Pineau, Fanny, additional, Vidal, Tiphaine, additional, Pomies, Elsa, additional, Bayet, Virginie, additional, Lesage, Suzanne, additional, Tahiri, Khadija, additional, Bertrand, Hélène, additional, Mallet, Alain, additional, Villeret, Coralie, additional, Mazmanian, Merry, additional, Manseur, Hakima, additional, Hajji, Mostafa, additional, Le Toullec, Benjamin, additional, Brochard, Vanessa, additional, Roy, Monica, additional, Rieu, Isabelle, additional, Bernard, Stéphane, additional, and Faurie-Grepon, Antoine, additional

Published
2020
Full Text
View/download PDF

9. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy

Author

Drapier, Sophie, Eusebio, Alexandre, Degos, Bertrand, Azulay, Jean Philippe, Viallet, François, Moreau, Caroline, Fraix, Valérie, Tranchant, Christine, Andre, Karine, Courbon, Christine, Roze, Emmanuel, Devos, David, Leclair-Visonneau, Laurène, Debilly, Bérangère, Durif, Franck, Houeto, Jean-Luc, Defebvre, Luc, Lamy, Estelle, Volteau, Christelle, Nguyen, Jean-Michel, Dily, Séverine Le, Damier, Philippe, Boutoleau-Bretonnière, Claire, Lejeune, Pascal, Derkinderen, Pascal, Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire Parole et Langage (LPL), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), ANTE-INSERM U836, équipe 10, Dynamique des réseaux neuronaux du mouvement, UM des troubles du mouvement, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Département de Neurologie, CHU Strasbourg-Hopital Civil, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de neurologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Plateforme de Biométrie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Centre Hospitalier Intercommunal, Centre Hospitalier Départemental, Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Collège de France (CdF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-PSL Research University (PSL)-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Troubles cognitifs dégénératifs et vasculaires (U1171), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-INSERM, Clinical and translational research in skin cancer (CRCINA - Département INCIT - Equipe 2), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)

Subjects
0301 basic medicine, Male, medicine.medical_specialty, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Placebo-controlled study, Placebo, Placebo group, Progressive supranuclear palsy, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, Rating scale, law, Internal medicine, Clinical endpoint, Medicine, Humans, Treatment Failure, Enzyme Inhibitors, ComputingMilieux_MISCELLANEOUS, Aged, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Valproic Acid, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, General Medicine, Middle Aged, medicine.disease, 3. Good health, Surgery, 030104 developmental biology, Tolerability, lipids (amino acids, peptides, and proteins), Female, Neurology (clinical), Supranuclear Palsy, Progressive, business, 030217 neurology & neurosurgery
Abstract

Objectives Results from preclinical studies suggest that inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease progression in progressive supranuclear palsy (PSP). Patients and methods We performed a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA (1500 mg/day) or matching placebo for 24 months. The primary endpoint was the change from baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at 12 and 24 months. Secondary endpoints evaluated the effects of VPA on cognitive and behavioral status (MMSE, Mattis Dementia Rating Scale, Wisconsin Card Sorting, Grober and Buschke and Oral Denomination 80 tests), tolerability of treatment, and patient compliance. Results There were no baseline differences between active treatment and placebo groups in age and clinical rating scores. PSPRS score at 12 months was significantly higher in the VPA than in the placebo group (60.8 ± 20 versus 46.9 ± 18.6 respectively, p = 0.01), but was similar between the two groups at 24 months. No significant differences were observed between VPA and placebo groups for the secondary endpoints. Conclusion Our results suggest that VPA is not effective as a disease-modifying agent in PSP.

Published
2015

10. Subthalamus stimulation in Parkinson disease: Accounting for the bilaterality of contacts

Author

Lemaire, Jean-Jacques, primary, Pereira, Bruno, additional, Derost, Philippe, additional, Vassal, François, additional, Ulla, Miguel, additional, Morand, Dominique, additional, Coll, Guillaume, additional, Gabrillargues, Jean, additional, Marques, Ana, additional, Debilly, Bérangère, additional, Coste, Jérôme, additional, and Durif, Franck, additional

Published
2016
Full Text
View/download PDF

12. Deep brain stimulation in routine clinical practice: monocentric study of the battery lifetime of different generations of neurostimulators.

Author

De Schlichting, Emmanuel, Marques, Ana-Raquel, Mulliez, Aurélien, Gampourou, Francois, Derost, Philippe, Debilly, Bérangère, Coste, Jérôme, Coll, Guillaume, Durif, Franck, and Lemaire, Jean-Jacques

Abstract

Routine clinical practice of Deep Brain Stimulation (DBS) enters a new era where battery-related events are challenging. The important number of primary implantations and replacements pushed industrials to develop new generations of devices. We aimed to analyze the battery lifetime of different kinds of non-rechargeable devices, manufactured by a single company (Medtronic, USA): the first generation of 4-contact neurostimulator for one DBS-lead (1 channel; Soletra®) and 8-contact neurostimulator for two DBS-leads (two channels of 4 contacts; Kinetra®); the second generation of advanced programming neurostimulator (Activa® PC, two channels of 8 contacts, and SC, 1 channel of 8 contacts). We retrospectively reviewed 281 consecutive patients operated on in a single institution (from 1995 to 2016): 584 surgeries for primary implantation or replacement of neurostimulator (infection and traumatic etiologies of battery replacement were excluded). The battery lifetime was defined as the period between the surgical implantation and the removal at battery depletion. Two hundred and eighty eight battery-lifetimes were analyzed in 157 patients suffering of Parkinson disease (n=129), essential tremor (n=19), dystonia (n=9). Exclusion criteria were: battery related, still operational (n=217); patient related, died before battery depletion (n=50); missing follow-up (n=3); and other diseases treated by DBS (n=2). Battery lifetime was analyzed using survival methods (univariate, Log-Rank test; multivariate, marginal cox model; two-sided tests) accounting for the following parameters: gender, neurological disease, age at the primary implantation, the UPDRS-score before DBS surgery, the deep brain target, battery model, mean voltage (low < 2V; usual from 2V to 4V; high v> 4V), location of battery (abdominal or sub clavicular) and presence of an adapter for replacement of first generation (Kinetra or Soletra) by second generation model (Activa).Results: The battery lifetime was shorter in male (p=0.03) and young (p<0.001) patients suffering of essential tremor (p<0.001) and dystonia (p<0.001). High voltage reduced battery lifetime (p<0.001). The second generation device, Activa models, had shorter lifetime than first generation, Soletra and Kinetra (p<0.001). Replacement of battery decreased lifetime independently of models (p<0.001). Patient and disease characteristics, high voltage, second generation devices and replacement seem to shorten lifetime of battery. [ABSTRACT FROM AUTHOR]

Published
2017

13. Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS.

Author

Chassain, Carine, Cladiere, Aurélie, Tsoutsos, Camille, Pereira, Bruno, Boumezbeur, Fawzi, Debilly, Bérangère, Marques, Ana-Raquel, Thobois, Stéphane, and Durif, Franck

Subjects
*PARKINSON'S disease, *GLUTAMIC acid, *NUCLEAR magnetic resonance spectroscopy, *GLUTAMINE, *SYMPTOMS
Abstract

Introduction: To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models.Methods: 1H NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2-3 years of disease progression. Statistical analysis used random-effects models.Results: The only significant difference between PD patients and controls was a higher glutamine (Gln) concentration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 ± 0.4 mM vs. 5.2 ± 0.2 mM, p < 0.05; Visit 2: 6.2 ± 0.3 mM vs. 5.2 ± 0.2 mM, p < 0.05). At Visit 1, PD patients had higher Glu and Gln levels in the putamen ipsilateral versus contralateral to dominant clinical signs (Glu: 12.2 ± 0.6 mM vs. 10.4 ± 0.6 mM, p < 0.05; Gln: 6.0 ± 0.4 mM vs. 4.8 ± 0.4 mM, p < 0.05; Glu and Gln pool (Glx): 17.9 ± 0.8 mM vs. 14.7 ± 1.1 mM, p < 0.05). At Visit 2, the sum of the two metabolites remained significantly higher in the ipsilateral versus contralateral putamen (Glx: 18.3 ± 0.6 mM vs. 16.1 ± 0.9 mM, p < 0.05).Conclusion: In de novo PD patients, the putamen ipsilateral to the more affected hemibody showed elevated Gln versus controls and elevated Glu and Gln concentrations versus the contralateral side. Abnormalities in Glu metabolism therefore occur early in PD but unexpectedly in the putamen contralateral to the more damaged hemisphere, suggesting they are not dependent solely on dopamine loss. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results